Minimal hepatic encephalopathy

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 12, 2007, Pages 677-685

  Stewart, Charmaine A ^a   Smith, Glenn E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTIBIOTIC AGENT; ANTIOXIDANT; CEFTRIAXONE; FLUORODEOXYGLUCOSE; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; LACTULOSE; MANGANESE; NEUROTOXIN; PLACEBO; PROBIOTIC AGENT; SELENIUM; WATER O 15;

ASTROCYTE; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DRIVING ABILITY; GLOBUS PALLIDUS; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEMORY DISORDER; METABOLIC ENCEPHALOPATHY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL; WORK DISABILITY;

DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; INCIDENCE; LACTULOSE; LIVER TRANSPLANTATION; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; WORLD HEALTH;

EID: 36649018910     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0999     Document Type: Review

References (84)

1. Ferenci P et al. (2002) Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35: 716-721
2. Das A et al. (2001) Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 16 531-535
3. Romero-Gomez M et al. (2001) Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 96: 2718-2723
4. Takano T et al. (2006) Astrocyte-mediated control of cerebral blood flow Nat Neurosci 9: 260-270
5. Olde Damink S et al. (2002) Interorgan ammonia and amino acids metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 36: 1163-1171
6. Lockwood AH et al. (1991) Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 11: 331-336
7. Lockwood AH et al. (1991) Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 11: 337-341
8. Guevara M et al. (1998) Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 28: 39-44
9. Barnes EM Jr et al. (1983) Role of glutamine synthetase in the uptake and metabolism of methylammonium by Azotobacter vinelandii. J Bacteriol 156: 752-757
10. Jayakumar A and Barnes EM Jr (1984) The role of glutamine in regulation of ammonium transport in Azotobacter vinelandii. Arch Biochem Biophys 231: 95-101
11. Jayakumar A et al. (1986) Role of the Escherichia coli gInALG operon in regulation of ammonium transport. J Bacteriol 166: 281-284
12. Jayakumar A et al. (1987) Feedback inhibition of ammonium (methylammonium) ion transport in Escherichia coli by glutamine and glutamine analogs. J Bacteriol 169: 553-557
13. Jayakumar A et al. (1989) Isolation of an ammonium or methylammonium ion transport mutant of Escherichia coli and complementation by the cloned gene. J Bacteriol 171: 996-1001
14. Bai G et al. (2001) Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes. J Neurosci Res 66: 981-991
15. Rama Rao KV et al. (2003) Ammonia neurotoxicity: Role of the mitochondrial permeability transition. Metab Brain Dis 18: 113-127
16. Rama Rao KV et al. (2003) Induction of the mitochondrial permeability transition in cultured astrocytes by glutamine. Neurochem Int 43: 517-523
17. Jayakumar AR et al. (2004) Glutamine-induced free radical production in cultured astrocytes. Glia 46: 296-301
18. Norenberg MD et al. (2004) Oxidative stress in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 19: 313-329
19. Norenberg MD et al. (2004) Ammonia neurotoxicity and the mitochondrial permeability transition. J Bioenerg Biomembr 36 303-307
20. Norenberg MD et al. (2005) Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis 20: 303-318
21. Rama Rao KV et al. (2005) Differential response of glutamine in cultured neurons and astrocytes. J Neurosci Res 79: 193-199
22. Jayakumar AR et al. (2006) Glutamine in the mechanism of ammonia-induced astrocyte swelling. Neurochem Int 48: 623-628
23. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65: 1-105
24. Chan N and Butterworth R (2006) Glutamatergic synaptic regulation deficit in liver failure: A review of molecular mechanisms. In Hepatic Encephalopathy and Nitrogen Metabolism, 160-170 (Eds Haussinger D et al.) Düsseldorf: Springer
25. Vaquero J and Butterworth RF (2006) The brain glutamate system in liver failure. J Neurochem 98: 661-669
26. Monfort P et al. (2005) Molecular mechanisms of the alterations in NMDA receptor-dependent long-term potentiation in hyperammonemia. Metab Brain Dis 20: 265-274
27. Corbalan B et al. (2002) Altered modulation of soluble guanylate cyclase in lymphocytes from patients with liver disease. J Mol Med 80: 117-123
28. Josephs KA et al. (2005) Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology 64: 2033-2039
29. Klos KJ et al. (2006) Brain metal concentrations in chronic liver failure patients with pallidall T1 MRI hyperintensity. Neurology 67: 1984-1989
30. Pujol A et al. (1993) Hyperintense globus pallidus on T1 -weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 43: 65-69
31. Lazeyras F et al. (2002) Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: A study on neuroradiological and blood manganese changes. Transpl Int 15: 188-195
32. Shawcross DL et al. (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40: 247-254
33. Wright GAK et al. (2006) The role of inflammation in hepatic encephalopathy. In Hepatic Encephalopathy and Nitrogen Metabolism, 229-242 (Eds Haussinger D et al.) Dordrecht: Springer
34. Minguez B et al. (2006) Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology 43: 707-714
35. Schomerus H and Hamster W (2001) Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 16: 37-41
36. Weissenborn K et al. (2001) Neuropsychological characterization of hepatic encephalopathy. J Hepatol 34: 768-773
37. Weissenborn K et al. (1990) Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol 75 289-295
38. Kulisevsky J et al. (1992) Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: Clinical correlations. Hepatology 16: 1382-1388
39. Lezak MD (1996) Neuropsychological Assessment. New York: Oxford University Press
40. McCrea M et al. (1996) Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 53 758-763
41. Folstein MF et al. (1975) Mini-Mental State: A practical method for grading the state of patients for the clinician, Journal of Psychiatric Research 12: 189-198
42. Tarter RE et al. (1987) Neurobehavioral correlates of cholestatic and hepatocellular disease: Differentiation according to disease specific characteristics and severity of the identified cerebral dysfunction. Int J Neurosci 32: 901-910
43. Tarter RE et al. (1984) Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. Gastroenterology 86: 1421-1427
44. Howieson DB and Lezak MD (2002) The neuropsychological evaluation. In Textbook of Neuropsychiatry and Clinical Neurosciences, 217-244 (Eds Yudofsky S and Hales RE) Washington, DC: American Psychiatric Publishing
45. Joebges EM et al. (2003) Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. J Hepatol 38: 273-280
46. Weissenborn K et al. (2005) Neurological and neuropsychiatric syndromes associated with liver disease. AIDS 19 (Suppl 3): S93-S98
47. Ortiz M et al. (2006) Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol 44: 104-110
48. Romero-Gomez M et al. (2007) Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 45: 879-885
49. Bajaj JS et al. (2007) Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol 102: 754-760
50. Rodriguez G et al. (1987) Reduction of cerebral blood flow in subclinical hepatic encephalopathy and its correlation with plasma-free tryptophan. J Cereb Blood Flow Metab 7: 768-772
51. O'Carroll RE et al. (1991) Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet 337: 1250-1253
52. Trzepacz PT et al. (1994) SPECT scan and cognitive findings in subclinical hepatic encephalopathy. J Neuropsychiatry Clin Neurosci 6: 170-175
53. Catafau AM et al. (2000) Relationship between cerebral perfusion in frontal-limbic-basal ganglia circuits and neuropsychologic impairment in patients with subclinical hepatic encephalopathy. J Nucl Med 41: 405-410
54. Morgan MY (1998) Cerebral magnetic resonance imaging in patients with chronic liver disease. Metab Brain Dis 13: 273-290
55. Malecki EA et al. (1999) Iron and manganese homeostasis in chronic liver disease: Relationship to pallidal T1-weighted magnetic resonance signal hyperintensity. Neurotoxicology 20: 647-652
56. Naegele T et al. (2000) MR imaging and (1)H spectroscopy of brain metabolites in hepatic encephalopathy: Time-course of renormalization after liver transplantation. Radiology 216:683-691
57. Weissenborn K et al. (2007) Correlations between MRS alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy. Gut [doi:10.1136/ gut.2006.110569]
58. Huda A et al. (1998) Clinical correlation of neuropsychological tests with 1H magnetic resonance spectroscopy in hepatic encephalopathy. Psychosom Med 60: 550-556
59. Lockwood AH et al. (1993) Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology 18: 1061-1068
60. Lockwood AH et al. (2002) Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics. Metab Brain Dis 17: 29-40
61. Kale RA et al. (2006) Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 43: 698-706
62. Younossi Z et al. (2001) Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 96: 579-583
63. Groeneweg M et al. (1998) Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 28: 45-49
64. Groeneweg M et al. (2000) Screening of subclinical hepatic encephalopathy. J Hepatol 32: 748-753
65. Marchesini G et al. (2001) Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 120: 170-178
66. Watanabe A et al. (1995) Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis 10: 239-248
67. Nyberg S et al. (2006) Early expedence with HEADS (hepatic encephalopathy assessment driving simulator) Advances in Transportation Studies: An International Journal: 2006 special issue, 5-15
68. Wain C et al. (2004) Minimal hepatic encephalopathy impairs fitness to drve. Hepatology 39: 739-745
69. Sanyal AJ et al. (2006) Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43: 682-689
70. Stewart C et al. (2007) Hepatic encephalopathy as a predictor of survival in patients with end stage liver disease. Liver Transplantation 13: 1366-1371
71. D'Amico G et al. (2006) Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 44: 217-231
72. Abraldes JG et al. (2003) Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37: 902-908
73. Merkel C et al. (1989) Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding. Am J Gastroenterol 84: 717-722
74. Bustamante J et al. (1999) Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 30: 890-895
75. Romero-Gomez M et al. (2004) Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 39: 939-943
76. Quero JC and Schalm SW (1996) Subclinical hepatic encephalopathy. Semin Liver Dis 16: 321-328
77. Watanabe A et al. (1997) Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 26: 1410-1414
78. Liu Q et al. (2004) Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39: 1441-1449
79. Mattarozzi K et al. (2004) Minimal hepatic encephalopathy: longitudinal effects of liver transplantation. Arch Neurol 61 242-247
80. Mechtcheriakov S et al. (2004) Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transpl 10: 77-83
81. Hockerstedt K et al. (1992) Encephalopathy and neuropathy in end-stage liver disease before and after liver transplantation. J Hepatol 16: 31-37
82. Prasad S et al. (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45: 549-559
83. Steinbrenner H et al. (2006) Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic Biol Med 40: 1513-1523
84. Rothstein JD et al. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77